Fortress Biotech, Inc. (FBIO): Operating Income
-$70.22M
Year ended 2025-12-31
-$29.18M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$70.22M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$110.38M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$142.34M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$203.56M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$188.54M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$94.27M | n/m | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | -$110.82M | n/m | 2021-04-09, From 2019-01-01 |
| 2018-12-31 | -$120.00M | n/m | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | -$89.80M | n/c | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | -$65.71M | n/m | 2018-03-16, From 2016-01-01 |
| 2015-12-31 | -$50.53M | n/m | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | -$20.65M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$35.78M | n/m | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | -$27.18M | n/m | 2015-03-16, From 2012-01-01 |
| 2011-12-31 | -$35.04M | n/m | 2014-03-14, From 2011-01-01 |
| 2010-12-31 | -$9.24M | n/m | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | -$2.61M | n/a | 2012-03-29, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | -$70.22M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$213.06M | n/m |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$111.29M | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$85.35M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$8.17M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $6.31M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$303.63M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$4.69M | n/m |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | -$8.31M | n/m |
Compare FBIO, NUVB, TNGX, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗